Potential Role of the Fragile Histidine Triad in Cancer Evo-Dev

被引:8
|
作者
Niu, Zheyun [1 ]
Jiang, Dongming [1 ]
Shen, Jiaying [1 ]
Liu, Wenbin [2 ,3 ,4 ]
Tan, Xiaojie [2 ,3 ,4 ]
Cao, Guangwen [1 ,2 ,3 ,4 ]
机构
[1] Sch Med Tongji Univ, Shanghai East Hosp, Key Lab Arrhythmias, Minist Educ,Sch Med, Shanghai 200120, Peoples R China
[2] Shanghai Key Lab Med Bioprotect, Shanghai 200433, Peoples R China
[3] Minist Educ, Key Lab Biol Def, Shanghai 200433, Peoples R China
[4] Second Mil Med Univ, Dept Epidemiol, Shanghai 200433, Peoples R China
关键词
fragile histidine triad; cancer evolution; genomic instability; retro-differentiation; APOBEC3; FHIT GENE; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; TUMOR-SUPPRESSOR; DOWN-REGULATION; ALLELIC LOSS; LUNG-CANCER; CELL-LINES; APOBEC3B; INFLAMMATION;
D O I
10.3390/cancers15041144
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Tumor development follows an evolutionary pattern of "mutation-selection-adaptation", characterized by exogenous oncogenic induction and endogenous replicative stress. The fragile histidine triad (FHIT) is a tumor suppressor. Aberrant transcription or reduction in the transcription and translation of the FHIT is an early event occurring in at least 50% of preneoplastic lesions and human cancers. Here, we summarized the evidence of the FHIT in cancers and evaluated the role of the FHIT in bridging macroevolution and microevolution and its functions in critical aspects of cancer evolutionary development (Cancer Evo-Dev), a theory developed to elucidate the mechanisms of non-resolving inflammation-induced carcinogenesis and develop suitable prophylactic and therapeutic options for malignant diseases. Cancer development follows an evolutionary pattern of "mutation-selection-adaptation" detailed by Cancer Evolution and Development (Cancer Evo-Dev), a theory that represents a process of accumulating somatic mutations due to the imbalance between the mutation-promoting force and the mutation-repairing force and retro-differentiation of the mutant cells to cancer initiation cells in a chronic inflammatory microenvironment. The fragile histidine triad (FHIT) gene is a tumor suppressor gene whose expression is often reduced or inactivated in precancerous lesions during chronic inflammation or virus-induced replicative stress. Here, we summarize evidence regarding the mechanisms by which the FHIT is inactivated in cancer, including the loss of heterozygosity and the promoter methylation, and characterizes the role of the FHIT in bridging macroevolution and microevolution and in facilitating retro-differentiation during cancer evolution and development. It is suggested that decreased FHIT expression is involved in several critical steps of Cancer Evo-Dev. Future research needs to focus on the role and mechanisms of the FHIT in promoting the transformation of pre-cancerous lesions into cancer.
引用
收藏
页数:15
相关论文
共 50 条
  • [11] Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model
    Guo, ZY
    Johansson, SL
    Rhim, JS
    Vishwanatha, JK
    PROSTATE, 2000, 43 (02): : 101 - 110
  • [12] Alteration of the fragile histidine triad gene in intrahepatic cholangiocarcinoma
    Koch, E
    Fiedler, W
    Tannapfel, A
    Ballhausen, WG
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (08) : 907 - 913
  • [13] Expression of the Fragile Histidine Triad Gene in Laryngeal Carcinoma
    Tutar, Ediz
    Karatas, Erkan
    Baglam, Tekin
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2010, 20 (04): : 229 - 234
  • [14] Fragile Histidine Triad Gene Inactivation in Lung Cancer The European Early Lung Cancer Project
    Verri, Carla
    Roz, Luca
    Conte, Davide
    Liloglou, Triantafillos
    Livio, Anna
    Vesin, Aurelien
    Fabbri, Alessandra
    Andriani, Francesca
    Brambilla, Christian
    Tavecchio, Luca
    Calarco, Giuseppe
    Calabro, Elisa
    Mancini, Andrea
    Tosi, Diego
    Bossi, Paolo
    Field, John K.
    Braimbilla, Elisabeth
    Sozzi, Gabriella
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179 (05) : 396 - 401
  • [15] Decreased fragile histidine triad expression in colorectal cancer and its association with apoptosis inhibition
    Cao, Jie
    Chen, Xiao-Ping
    Li, Wang-Lin
    Xia, Jie
    Du, Hong
    Tang, Wei-Biao
    Wang, Hui
    Chen, Xi-Wen
    Xiao, Huan-Qing
    Li, Yu-Yuan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (07) : 1018 - 1026
  • [16] Investigation of the promoter methylation status of the FHIT (fragile histidine triad) gene in larynx cancer
    Demokan, Semra
    Akalin, Kubra
    Ozkoklesen, Cansu
    Ulusan, Murat
    Enver, Necati
    Daley, Nejat
    CANCER RESEARCH, 2016, 76
  • [17] Lack of association of fragile histidine triad (FHIT) polymorphisms with lung cancer in the Korean population
    Hae-Yun Jung
    Jae Sook Sung
    Young Mi Whang
    Hyoung Doo Shin
    Byung Lae Park
    Jun Suk Kim
    Sang Won Shin
    Hee Yun Seo
    Hwa Jung Sung
    In Keun Choi
    Sang Cheul Oh
    Jae Hong Seo
    Yeul Hong Kim
    Journal of Human Genetics, 2007, 52
  • [18] The fragile histidine triad gene: A molecular link between cigarette smoking and cervical cancer
    Holschneider, CH
    Baldwin, RL
    Tumber, K
    Aoyama, C
    Karlan, BY
    CLINICAL CANCER RESEARCH, 2005, 11 (16) : 5756 - 5763
  • [20] Lack of association of fragile histidine triad (FHIT) polymorphisms with lung cancer in the Korean population
    Jung, Hae-Yun
    Sung, Jae Sook
    Whang, Young Mi
    Shin, Hyoung Doo
    Park, Byung Lae
    Kim, Jun Suk
    Shin, Sang Won
    Seo, Hee Yun
    Sung, Hwa Jung
    Choi, In Keun
    Oh, Sang Cheul
    Seo, Jae Hong
    Kim, Yeul Hong
    JOURNAL OF HUMAN GENETICS, 2007, 52 (08) : 668 - 674